DOCSLIB.ORG

Ductal Carcinoma in Situ

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ductal Carcinoma in Situ Breast Cancer Definition of Ductal Carcinoma In Situ Terms What is Ductal Carcinoma What characterizes DCIS? Ductal: Relating In Situ (DCIS)? DCIS is characterized by pre-can- to the breast’s milk Ductal Carcinoma In Situ is the cerous or early-stage cell abnor- ducts, the parts of the earliest possible and most treat- malities in the breast ducts. On a breast through which able diagnosis of breast cancer. mammogram, DCIS appears as milk fl ows. Some experts consider it to be areas of calcifi cation. “pre-malignant.” The most com- Carcinoma: A type mon form of non-invasive breast How does the pathologist of cancerous, or ma- cancer, DCIS accounts for about make a diagnosis? lignant, tumor. 25 percent of all breast cancers. The pathologist examines biopsy Sometimes, DCIS is seen in as- specimens, In Situ: In its original sociation with an invasive form of along with place. breast cancer. other tests if The diagnosis of DCIS is in- necessary. If Non-invasive: Not spreading beyond the creasing because more women are mammogra- inside of the breast receiving regular mammograms phy shows duct. – and because of advancements in suspicious mammography technology, which fi ndings, a Calcifi cation: Cal- can now fi nd small areas of calci- biopsy may cium deposits in the fi cation in the breast. If untreated, be recom- breast can be associ- about 30 percent of women with mended. A ated with Ductal Car- DCIS will develop invasive breast biopsy is the Ductal Carcinoma cinoma In Situ. Clus- cancer within 10 years of the ini- most widely used method for In Situ is the earliest ters of these deposits tial making a fi rm diagnosis of breast possible and most may indicate cancer. diagnosis. cancer. During a biopsy proce- treatable form of dure, a primary care physician breast cancer. Malignant: Cancer- Who is most likely to have removes cells or tissues from the ous and capable of DCIS? suspicious area for the pathologist spreading. Because of how DCIS is de- to examine more closely in the tected, it can be found in women laboratory. In Pathologist: A physi- earlier than age 45, which is the some cases a cian who examines age breast cancer becomes more biopsy may tissues and fl uids common. However, as a woman be performed to diagnose disease ages, breast cancer risk does not with surgery. in order to assist in decline; therefore, DCIS can be To make a making treatment de- fi rm diagnosis cisions. found at any age. About 20 per- cent of women with breast cancer of DCIS, the have a family history of the dis- pathologist ease. will investi- Other factors increasing the risk gate whether Normal breast cells. of having breast cancer include the malignan- having no children or the fi rst cy has invaded tissue surrounding child after age 30, early men- the ducts. A diagnosis of DCIS means the tumor remains only in Copyright © 2006 struation, and consuming three or College of American more alcoholic drinks its original place – “in situ.” Pathologists. For use and a day. reproduction by patients and CAP members only. First edition, Dec. 2006. What else does the All DCIS tumors are Stage “Tis,” which means pathologist look for? The biopsy sample is tested for the tumor is “in situ” and has not spread. The the presence of estrogen recep- tors. Women with DCIS contain- cure rate for stage “Tis” tumors is close to 100 ing this receptor are more likely percent if standard forms of treatment are fol- to respond positively to hormone therapy. Due to continual advanc- lowed. es in research, other tests may be used as well. Advancements in surgical What kinds of With all necessary tests com- techniques have enabled about questions should pleted, pathologists determine 70 percent of women to choose I ask my doctors? It’s important the cancer’s stage. All DCIS breast-conserving surgical treat- to learn as tumors are Stage “Tis,” which ments like lumpectomy rather Ask any question means the tumor is “in situ” and than mastectomy, where the you want. There are much as you has not spread. The cure rate for entire breast is removed. If you no questions you stage “Tis” tumors is close to 100 have DCIS, which is confi ned to should be reluctant can about percent if standard forms of treat- one area of one breast, you are to ask. Here are a your treatment ment are followed. likely to be a good candidate for few to consider: lumpectomy. If your breast cannot options and How do doctors determine be conserved, breast reconstruc- • Please describe what surgery or treatment tion surgery may be a possibility the type of cancer I to make the will be necessary? after you recover from your initial have and what treat- decision that’s The pathologist consults with operation to remove ment options are your primary care physician the cancer. available. right after reviewing the test results. Radiation therapy is often used Together, using their combined after lumpectomy and sometimes • What are the for you. experience and knowledge, they after mastectomy to rid the body chances for full determine treatment options most of any microscopic remnants of remission? appropriate for your condition. the cancer in the area where the original tumor was found and re- • What treatment What kinds of treatments moved. options do you rec- are available for DCIS? ommend? Why do DCIS is treated through surgery, For more information, go to you believe these are which is sometimes supplemented www.cancer.org (American Can- the best by radiation therapy. It’s impor- cer Society) or www.y-me.org. treatments? tant to learn as much as you can about your treatment options and • What are the pros to make the decision that’s right and cons of these for you. Because having DCIS is treatment options? not an emergency situation, you can take your time making your • What are the choices. side effects? • Should I receive a second opinion? • Is your medical team experienced in treating the type of cancer I have? • Can you provide me with information about the physicians .
Load more

Recommended publications
  • Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC)
    Scientific Framework for Pancreatic Ductal Adenocarcinoma (PDAC) National Cancer Institute February 2014 1 Table of Contents Executive Summary 3 Introduction 4 Background 4 Summary of the Literature and Recent Advances 5 NCI’s Current Research Framework for PDAC 8 Evaluation and Expansion of the Scientific Framework for PDAC Research 11 Plans for Implementation of Recommended Initiatives 13 Oversight and Benchmarks for Progress 18 Conclusion 18 Links and References 20 Addenda 25 Figure 1: Trends in NCI Funding for Pancreatic Cancer, FY2000-FY2012 Figure 2: NCI PDAC Funding Mechanisms in FY2012 Figure 3: Number of Investigators with at Least One PDAC Relevant R01 Grant FY2000-FY2012 Figure 4: Number of NCI Grants for PDAC Research in FY 2012 Awarded to Established Investigators, New Investigators, and Early Stage Investigators Table 1: NCI Trainees in Pancreatic Cancer Research Appendices Appendix 1: Report from the Pancreatic Cancer: Scanning the Horizon for Focused Invervention Workshop Appendix 2: NCI Investigators and Projects in PDAC Research 2 Scientific Framework for Pancreatic Ductal Carcinoma Executive Summary Significant scientific progress has been made in the last decade in understanding the biology and natural history of pancreatic ductal adenocarcinoma (PDAC); major clinical advances, however, have not occurred. Although PDAC shares some of the characteristics of other solid malignancies, such as mutations affecting common signaling pathways, tumor heterogeneity, development of invasive malignancy from precursor lesions,
    [Show full text]
  • DCIS): Pathological Features, Differential Diagnosis, Prognostic Factors and Specimen Evaluation
    Modern Pathology (2010) 23, S8–S13 S8 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 Ductal carcinoma in situ (DCIS): pathological features, differential diagnosis, prognostic factors and specimen evaluation Sarah E Pinder Breast Research Pathology, Research Oncology, Division of Cancer Studies, King’s College London, Guy’s Hospital, London, UK Ductal carcinoma in situ (DCIS) is a heterogeneous, unicentric precursor of invasive breast cancer, which is frequently identified through mammographic breast screening programs. The lesion can cause particular difficulties for specimen handling in the laboratory and typically requires even more diligent macroscopic assessment and sampling than invasive disease. Pitfalls and tips for macroscopic handling, microscopic diagnosis and assessment, including determination of prognostic factors, such as cytonuclear grade, presence or absence of necrosis, size of the lesion and distance to margins are described. All should be routinely included in histopathology reports of this disease; in order not to omit these clinically relevant details, synoptic reports, such as that produced by the College of American Pathologists are recommended. No biomarkers have been convincingly shown, and validated, to predict the behavior of DCIS till date. Modern Pathology (2010) 23, S8–S13; doi:10.1038/modpathol.2010.40 Keywords: ductal carcinoma in situ (DCIS); breast cancer; histopathology; prognostic factors Ductal carcinoma in situ (DCIS) is a malignant, lesions, a good cosmetic result can be obtained by clonal proliferation of cells growing within the wide local excision. Recurrence of DCIS generally basement membrane-bound structures of the breast occurs at the site of previous excision and it is and with no evidence of invasion into surrounding therefore better regarded as residual disease, as stroma.
    [Show full text]
  • A Case of Renal Cell Carcinoma Metastasizing to Invasive Ductal Breast Carcinoma Tai-Di Chen, Li-Yu Lee*
    Journal of the Formosan Medical Association (2014) 113, 133e136 Available online at www.sciencedirect.com journal homepage: www.jfma-online.com CASE REPORT A case of renal cell carcinoma metastasizing to invasive ductal breast carcinoma Tai-Di Chen, Li-Yu Lee* Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Guishan Township, Taoyuan County, Taiwan, ROC Received 12 December 2009; received in revised form 20 May 2010; accepted 1 July 2010 KEYWORDS Tumor-to-tumor metastasis is an uncommon but well-documented phenomenon. We present breast carcinoma; a case of a clear cell renal cell carcinoma (RCC) metastasizing to an invasive ductal carcinoma invasive ductal (IDC)ofthebreast.A74-year-oldwomanwitha past history of clear cell RCC status after carcinoma; radical nephrectomy underwent right modified radical mastectomy for an enlarging breast renal cell carcinoma; mass 3 years after nephrectomy. Histological examination revealed a small focus with distinct tumor-to-tumor morphological features similar to clear cell RCC encased in the otherwise typical IDC. Immu- metastasis nohistochemical studies showed that this focus was positive for CD10 and vimentin, in contrast to the surrounding IDC, which was negative for both markers and positive for Her2/neu. Based on the histological and immunohistochemical features, the patient was diagnosed with metas- tasis of clear cell RCC to the breast IDC. To the best of our knowledge, this is the first reported case of a breast neoplasm as the recipient tumor in tumor-to-tumor metastasis. Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved. Introduction tumor is renal cell carcinoma (RCC, 38.8%), followed by meningioma (25.4%), and the most frequent donor tumor is The phenomenon of tumor-to-tumor metastasis was first lung cancer (55.8%).
    [Show full text]
  • Understanding Ductal Carcinoma in Situ (DCIS)
    Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Understanding ductal carcinoma in situ (DCIS) and deciding about treatment Developed by National Breast and Ovarian Cancer Centre Funded by the Australian Government Department of Health and Ageing Understanding ductal carcinoma in situ Contents Acknowledgements .........................................................................................2 How to use this resource ..............................................................................3 Introduction ...........................................................................................................4 Why do I need treatment for DCIS? .........................................................5 Surgery ......................................................................................................................7 Radiotherapy ......................................................................................................11 What is the risk of developing invasive breast cancer or Understanding ductal carcinoma in situ (DCIS) and deciding about treatment was prepared and produced by: DCIS after treatment? ....................................................................................12 National Breast and Ovarian Cancer Centre What follow-up will I need? .......................................................................17 Level 1 Suite 103/355 Crown Street Surry Hills NSW 2010 How can I get more emotional support? .........................................18 Locked Bag 3
    [Show full text]
  • Metastatic Renal Cell Cancer Presenting As a Breast Mass
    H & 0 C l i n i C a l C a s e s t u d i e s Metastatic Renal Cell Cancer Presenting as a Breast Mass Neeta Pathe, MD Department of Hematology and Oncology, Allegheny General Hospital, Jane Raymond, MD Pittsburgh, Pennsylvania Alice Ulhoa Cintra, MD introduction a focus of residual DCIS extending to the lateral resec- tion margin. The 2 sentinel lymph nodes examined Metastases to the breast are uncommon, and demand an were benign. Two weeks after her surgery, the patient accurate and prompt diagnosis due to differences in prog- complained of increased swelling on the medial side of nosis and management from primary breast cancer. Here the left breast. This swelling was re-evaluated by a repeat we describe a case of renal cell cancer metastasizing to the ultrasound, which showed an unchanged size of the oval breast 10 years after nephrectomy for the primary tumor. mass and mixed echogenicity. Historically, the prognosis for such a patient has been Preoperatively, a chest X-ray revealed a 6-mm right extremely poor. In the era of novel therapies, however, we lung nodule, and a computed tomography (CT) scan was are now able to provide treatment with an oral agent and recommended for follow-up. The CT scan of the chest, achieve an excellent response. which was performed approximately 3 months after the right lumpectomy, revealed multiple bilateral pulmonary Case study nodules measuring 4–5 mm. Additionally, the lesion in the left breast had increased to 2.7 × 1.9 cm and was suspicious A 64-year-old African American woman with a history for metastatic disease (Figure 1).
    [Show full text]
  • Large Duct Type Invasive Adenocarcinoma of the Pancreas with Microcystic and Papillary Patterns: a Potential Microscopic Mimic of Non-Invasive Ductal Neoplasia
    Modern Pathology (2012) 25, 439–448 & 2012 USCAP, Inc. All rights reserved 0893-3952/12 $32.00 439 Large duct type invasive adenocarcinoma of the pancreas with microcystic and papillary patterns: a potential microscopic mimic of non-invasive ductal neoplasia Pelin Bagci1, Aleodor A Andea2, Olca Basturk3, Kee-Taek Jang4,IpekErbarut5 and Volkan Adsay5 1Department of Pathology, Rize University, School of Medicine, Rize, Turkey; 2Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA; 3Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York City, NY, USA; 4Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea and 5Department of Pathology, Emory University, Atlanta, GA, USA A morphological variant of pancreatic ductal adenocarcinoma forming large ductal elements, large duct type ductal adenocarcinoma, is documented and its clinicopathological features are studied. These tumors may have microcystic and papillary growth patterns that closely mimic the non-invasive cystic and papillary pancreatic tumors such as: intraductal papillary-mucinous neoplasia, including the oncocytic variant, mucinous cystic neoplasms, and ducts involved by pancreatic intraepithelial neoplasia. In a review of 230 pancreatectomy specimens with ductal adenocarcinoma, 28 (8%) cases of large duct type ductal adenocarcinomas were identified according to following criteria: more than 50% of the tumor sections available for examination contained infiltrative ducts with a diameter larger than 0.5 mm or had a macroscopically identifiable microcystic pattern. Overall characteristics of large duct type ductal adenocarcinomas were not too different than those of conventional ductal adenocarcinomas, except that there was a slight female predominance in the former (F/M ¼ 2.3).
    [Show full text]
  • Liver, Gallbladder, Bile Ducts, Pancreas
    Liver, gallbladder, bile ducts, pancreas Coding issues Otto Visser May 2021 Anatomy Liver, gallbladder and the proximal bile ducts Incidence of liver cancer in Europe in 2018 males females Relative survival of liver cancer (2000 10% 15% 20% 25% 30% 35% 40% 45% 50% 0% 5% Bulgaria Latvia Estonia Czechia Slovakia Malta Denmark Croatia Lithuania N Ireland Slovenia Wales Poland England Norway Scotland Sweden Netherlands Finland Iceland Ireland Austria Portugal EUROPE - Germany 2007) Spain Switzerland France Belgium Italy five year one year Liver: topography • C22.1 = intrahepatic bile ducts • C22.0 = liver, NOS Liver: morphology • Hepatocellular carcinoma=HCC (8170; C22.0) • Intrahepatic cholangiocarcinoma=ICC (8160; C22.1) • Mixed HCC/ICC (8180; TNM: C22.1; ICD-O: C22.0) • Hepatoblastoma (8970; C22.0) • Malignant rhabdoid tumour (8963; (C22.0) • Sarcoma (C22.0) • Angiosarcoma (9120) • Epithelioid haemangioendothelioma (9133) • Embryonal sarcoma (8991)/rhabdomyosarcoma (8900-8920) Morphology*: distribution by sex (NL 2011-17) other other ICC 2% 3% 28% ICC 56% HCC 41% HCC 70% males females * Only pathologically confirmed cases Liver cancer: primary or metastatic? Be aware that other and unspecified morphologies are likely to be metastatic, unless there is evidence of the contrary. For example, primary neuro-endocrine tumours (including small cell carcinoma) of the liver are extremely rare. So, when you have a diagnosis of a carcinoid or small cell carcinoma in the liver, this is probably a metastatic tumour. Anatomy of the bile ducts Gallbladder
    [Show full text]
  • Enlarging Nodule on the Nipple
    PHOTO CHALLENGE Enlarging Nodule on the Nipple Caren Waintraub, MD; Brianne Daniels, DO; Shari R. Lipner, MD, PhD Eligible for 1 MOC SA Credit From the ABD This Photo Challenge in our print edition is eligible for 1 self-assessment credit for Maintenance of Certification from the American Board of Dermatology (ABD). After completing this activity, diplomates can visit the ABD website (http://www.abderm.org) to self-report the credits under the activity title “Cutis Photo Challenge.” You may report the credit after each activity is completed or after accumulating multiple credits. A healthy 48-year-old woman presented with a growth on the right nipple that had been slowly enlarging over the last few months. She initially noticed mild swellingcopy in the area that persisted and formed a soft lump. She described mild pain with intermittent drainage but no bleeding. Her medical history was unremarkable, including a negativenot personal and family history of breast and skin cancer. She was taking no medications prior to development of the mass. She had no recent history of pregnancy or breastfeeding. A mammo- Dogram and breast ultrasound were not concerning for carcinoma. Physical examination showed a soft, exophytic, mildly tender, pink nodule on the right nipple that measured 12×7 mm; no drainage, bleeding, or ulceration was present. The surround- ing skin of the areola and breast demonstrated no clinical changes. The contralateral breast, areola, and nipple were unaffected. The patient had no appreciable axillary or cervical lymphadenopathy. A deep shave biopsy of the noduleCUTIS was performed and sent for histopathologic examination.
    [Show full text]
  • Co-Existent Breast and Renal Cancer
    Ulus Cerrahi Derg 2015; 31: 238-40 Case Report DOI: 10.5152/UCD.2015.2874 Co-existent breast and renal cancer Orhan Üreyen1, Emrah Dadalı1, Fırat Akdeniz2, Tamer Şahin3, Mehmet Tahsin Tekeli1, Nuket Eliyatkın3, Hakan Postacı3, Enver İlhan1 ABSTRACT The concomitant presence of breast cancer with one or more other types of cancer such as colon, vulva, lung, larynx, liver, uterus and kidneys has been presented in the literature. However, synchronous breast and renal cancer is very uncommon. Herein we present a woman with synchronous breast and renal cancer, and review the literature. A 77-year-old post-menopausal woman was admitted to our clinic complaining of left sided breast mass. On physical examination, there was a 3 cm palpable mass in the upper outer quadrant of the left breast along with a conglom- erate of lymph nodes in the left axilla. Ultrasonography and mammography showed a 3 cm solid, hypoechoic mass in the upper outer quadrant and left axillary lymphadenopathy. The tru-cut biopsy of the lesion revealed invasive ductal carcinoma. The bone scintigraphy, thoracic and cranial computerized tomographies were normal. The ab- dominal computerized tomography identified a 3x3 cm solid renal mass with heterogeneous contrast enhancement in the posterior segment of the lower pole, which was suspicious for renal cell carcinoma. Breast conserving surgery and axillary lymph node dissection was performed, and the pathology specimen demonstrated invasive ductal car- cinoma. The patient was discharged on postoperative day 5. Three weeks later partial nephrectomy was performed by urology department for the solid renal mass, and the pathology result showed clear cell-renal carcinoma with Fuhrman grade 3.
    [Show full text]
  • Adenoid Cystic Carcinoma of the Breast Law Y M, Quek S T, Tan P H, Wong S L J
    Case Report Singapore Med J 2009; 50(1) : e8 Adenoid cystic carcinoma of the breast Law Y M, Quek S T, Tan P H, Wong S L J ABSTRACT depressants. Family history was negative for breast Adenoid cystic carcinoma of the breast is a and ovarian cancer. Menarche occurred at the age of rare neoplasm that constitutes less than one 12 years and she attained menopause at the age of 50 percent of all mammary carcinomas. To date, years. She was placed on hormone replacement therapy there have been about 140 cases reported in the postmenopausally for a period of less than five years. literature. It is a rare variant of adenocarcinoma She was married with no children. She did not smoke that usually occurs in the salivary glands. In or drink. Physical examination revealed a vaguely contrast to the aggressive nature of adenoid palpable 1 cm mass at the upper outer quadrant of the cystic carcinoma that occurs in the head and neck right breast. There were no skin changes nor was there region, adenoid cystic carcinoma of the breast nipple discharge. No palpable axillary adenopathy was has a very favourable prognosis. Little has been detected. published to date on its radiological features. Mammography revealed an asymmetric ill-defined We describe a 63-year-old woman with adenoid mass in the upper outer quadrant of the right breast, cystic carcinoma detected on mammography in approximately 5 cm from the nipple (Fig. 1). The our national breast screening programme, the patient was recalled for an assessment of the abnormal radiological findings at presentation, the surgical mammography finding through the breast screening management and a review of the literature.
    [Show full text]
  • Nipple Adenoma in a Female Patient Presenting with Persistent Erythema
    Spohn et al. BMC Dermatology (2016) 16:4 DOI 10.1186/s12895-016-0041-6 CASEREPORT Open Access Nipple adenoma in a female patient presenting with persistent erythema of the right nipple skin: case report, review of the literature, clinical implications, and relevancy to health care providers who evaluate and treat patients with dermatologic conditions of the breast skin Gina P. Spohn1*, Shannon C. Trotter1, Gary Tozbikian2 and Stephen P. Povoski3* Abstract Background: Nipple adenoma is a very uncommon, benign proliferative process of lactiferous ducts of the nipple. Clinically, it often presents as a palpable nipple nodule, a visible nipple skin erosive lesion, and/or with discharge from the surface of the nipple skin, and is primarily seen in middle-aged women. Resultantly, nipple adenoma can clinically mimic the presentation of mammary Paget’s disease of the nipple. The purpose of our current case report is to present a comprehensive review of the available data on nipple adenoma, as well as provide useful information to health care providers (including dermatologists, breast health specialists, and other health care providers) who evaluate patients with dermatologic conditions of the breast skin for appropriately clinically recognizing, diagnosing, and treating patients with nipple adenoma. Case presentation: Fifty-three year old Caucasian female presented with a one year history of erythema and induration of the skin of the inferior aspect of the right nipple/areolar region. Skin punch biopsies showed subareolar duct papillomatosis. The patient elected to undergo complete surgical excision with right central breast resection. Final histopathologic evaluation confirmed nipple adenoma. The patient is doing well 31 months after her definitive surgical therapy.
    [Show full text]
  • Characterization of Ductal Carcinoma in Situ Cell Lines Established From
    Yong et al. Cancer Cell International 2014, 14:94 http://www.cancerci.com/content/14/1/94 PRIMARY RESEARCH Open Access Characterization of ductal carcinoma in situ cell lines established from breast tumor of a Singapore Chinese patient Jacklyn WY Yong†, Meng Ling Choong†, SiFang Wang, Yu Wang, Shermaine QY Lim and May Ann Lee* Abstract Background: Five cell lines were established from a Singaporean patient of Chinese origin with breast ductal carcinoma in situ (DCIS). These five cell lines express exogenous human telomerase reverse transcriptase (hTERT) which confers the ability to proliferate indefinitely. Methods: Cells were isolated from the DCIS excision and transfected with a plasmid expressing hTERT, a catalytic subunit of telomerase. Five immortalized colonies were propagated and characterized by karyotyping, array comparative genomic hybridization (CGH), immunostaining and Western blots for biomarkers, in vitro anchorage independent growth, in vivo mouse tumorigenicity, drug sensitivity, species authentication and virology safety testing. Results: Array CGH analysis showed that the cell lines harbored different specific genetic aberrations. Common mutations observed in most breast cancer cell lines such as the general loss of heterozygosity (LOH) throughout chromosome X and chromosome 17 are also observed in our cell lines. The cell lines were further characterized as human breast cells that are estrogen- and progesterone-receptor positive, and sensitive to tamoxifen. The cell lines showed anchorage-independent growth in the soft agar assay and can grow in common culture medium without supplementation with growth factor, therefore demonstrating transformed characteristics. Four of the cell lines can engraft and form measureable tumors after 50 days when injected subcutaneously into immune-deficient (SCID) mice.
    [Show full text]